Breakthrough Therapy for Type 2 Diabetes and Obesity to be Highlighted at DDW
By Alex Escalona, MD
Type 2 diabetes and obesity are chronic diseases of growing proportions in Chile, as they are in the rest of the world. The most recent estimates from the International Diabetes Federation (IDF) indicate that type 2 diabetes affects approximately 320 million people worldwide and that 90% of these cases are caused by excess weight. Drug therapy can work well in some patients; however, it often becomes less effective over time and can lead to weight gain. Bariatric surgery can also be an effective option; however, it has serious safety and side effect risks, requires permanent changes to the anatomy and several weeks of recovery time.
In my practice, we are using a new, non-surgical approach called EndoBarrier® Therapy, to treat patients who have type 2 diabetes and are obese. EndoBarrier is a breakthrough, endoscopically-placed device that has been studied in 13 clinical trials with over 500 patients. It has been shown to achieve target HbA1c levels in 80% of patients, achieve weight loss of more than 20%, and improve important metabolic functions including cholesterol, blood sugar and triglycerides within a year.1 EndoBarrier is a thin, flexible, tube-shaped liner that works by creating a physical barrier between food and a portion of the intestinal wall. Food bypasses the duodenum and proximal jejunum which affects certain gastrointestinal hormones involved in insulin sensitivity, glucose metabolism and satiety.
With EndoBarrier Therapy, my patients report increased energy, feeling full for a longer period of time after eating, and immediate and continued weight loss. We have found that EndoBarrier Therapy has a rapid and sustained effect that enables patients to have a reduced reliance on diabetes medications, including insulin. In my practice, I use EndoBarrier Therapy for those patients whose type 2 diabetes and obesity can’t be well controlled with current medications or lifestyle changes. Patients tell us that they really like EndoBarrier Therapy because it is a simple procedure that is reversible; and they see improvements right away. They are also able to avoid long-term side effects such as anemia and nutritional deficiency that can be seen in patients who opt for a permanent surgical solution.
At this year’s DDW, I have the opportunity to demonstrate what EndoBarrier Therapy is and how it works during the workshop “Xtreme Endoscopic Toolbox: New and Cutting Edge Therapies” on Sunday, May 20, 7:30–10 a.m. This workshop will feature several of my esteemed colleagues and will be a hands-on presentation and interactive session to discuss emerging technologies currently in use worldwide for the endoscopic treatment of obesity.
If you are interested in new technologies and devices to help your patients who are struggling with type 2 diabetes and obesity, then please join us for this workshop.
Watch Dr. Escalona describe his presentation in English or Spanish:
 C de Jonge, JW Greve, N Bouvy, et al, EndoBarrier Gastrointestinal Liner treatment rapidly improves diabetes parameters paralleled by increased postprandial GLP-1 and PYY levels in obese type 2 diabetic patients, Department of Surgery, Maastricht University Medical Centre, presented at IFSO 2011, Hamburg, Germany.
Alex Escalona, MD is Assistant Professor of Surgery, Department of Digestive Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile